These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 32741818)

  • 1. Amyloidogenic Nanoplaques in Cerebrospinal Fluid: Relationship to Amyloid Brain Uptake and Clinical Alzheimer's Disease in a Memory Clinic Cohort.
    Aksnes M; Müller EG; Tiiman A; Edwin TH; Terenius L; Revheim ME; Vukojević V; Bogdanović N; Knapskog AB
    J Alzheimers Dis; 2020; 77(2):831-842. PubMed ID: 32741818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations of cerebrospinal fluid amyloidogenic nanoplaques with cytokines in Alzheimer's disease.
    Aksnes M; Aass HCD; Tiiman A; Edwin TH; Terenius L; Bogdanović N; Vukojević V; Knapskog AB
    Transl Neurodegener; 2021 Jun; 10(1):18. PubMed ID: 34099032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Cerebrospinal Fluid Amyloidogenic Nanoplaques With Core Biomarkers of Alzheimer's Disease.
    Aksnes M; Tiiman A; Edwin TH; Terenius L; Bogdanović N; Vukojević V; Knapskog AB
    Front Aging Neurosci; 2020; 12():608628. PubMed ID: 33488383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum Amyloidogenic Nanoplaques and Cytokines in Alzheimer's Disease: Pilot Study in a Small Naturalistic Memory Clinic Cohort.
    Aksnes M; Aass HCD; Tiiman A; Terenius L; Bogdanović N; Vukojević V; Knapskog AB
    J Alzheimers Dis; 2022; 86(3):1459-1470. PubMed ID: 35213378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amyloidogenic Nanoplaques in Blood Serum of Patients with Alzheimer's Disease Revealed by Time-Resolved Thioflavin T Fluorescence Intensity Fluctuation Analysis.
    Tiiman A; Jelić V; Jarvet J; Järemo P; Bogdanović N; Rigler R; Terenius L; Gräslund A; Vukojević V
    J Alzheimers Dis; 2019; 68(2):571-582. PubMed ID: 30814355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amyloid-β PET-Correlation with cerebrospinal fluid biomarkers and prediction of Alzheimer´s disease diagnosis in a memory clinic.
    Müller EG; Edwin TH; Stokke C; Navelsaker SS; Babovic A; Bogdanovic N; Knapskog AB; Revheim ME
    PLoS One; 2019; 14(8):e0221365. PubMed ID: 31430334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Towards the Integrative Theory of Alzheimer's Disease: Linking Molecular Mechanisms of Neurotoxicity, Beta-amyloid Biomarkers, and the Diagnosis.
    Molkov YI; Zaretskaia MV; Zaretsky DV
    Curr Alzheimer Res; 2023; 20(6):440-452. PubMed ID: 37605411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 18F-Flortaucipir PET Associations with Cerebrospinal Fluid, Cognition, and Neuroimaging in Mild Cognitive Impairment due to Alzheimer's Disease.
    Okafor M; Nye JA; Shokouhi M; Shaw LM; Goldstein F; Hajjar I
    J Alzheimers Dis; 2020; 74(2):589-601. PubMed ID: 32065800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Diagnostic Performances Between Cerebrospinal Fluid Biomarkers and Amyloid PET in a Clinical Setting.
    Jung NY; Kim ES; Kim HS; Jeon S; Lee MJ; Pak K; Lee JH; Lee YM; Lee K; Shin JH; Ko JK; Lee JM; Yoon JA; Hwang C; Choi KU; Lee EC; Seong JK; Huh GY; Kim DS; Kim EJ
    J Alzheimers Dis; 2020; 74(2):473-490. PubMed ID: 32039853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
    Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
    J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes.
    Carandini T; Arighi A; Sacchi L; Fumagalli GG; Pietroboni AM; Ghezzi L; Colombi A; Scarioni M; Fenoglio C; De Riz MA; Marotta G; Scarpini E; Galimberti D
    Alzheimers Res Ther; 2019 Oct; 11(1):84. PubMed ID: 31615545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer's disease: a literature review.
    Brand AL; Lawler PE; Bollinger JG; Li Y; Schindler SE; Li M; Lopez S; Ovod V; Nakamura A; Shaw LM; Zetterberg H; Hansson O; Bateman RJ
    Alzheimers Res Ther; 2022 Dec; 14(1):195. PubMed ID: 36575454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CSF biomarkers and amyloid PET: concordance and diagnostic accuracy in a MCI cohort.
    Spallazzi M; Barocco F; Michelini G; Immovilli P; Taga A; Morelli N; Ruffini L; Caffarra P
    Acta Neurol Belg; 2019 Sep; 119(3):445-452. PubMed ID: 30847669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms.
    Doecke JD; Rembach A; Villemagne VL; Varghese S; Rainey-Smith S; Sarros S; Evered LA; Fowler CJ; Pertile KK; Rumble RL; Trounson B; Taddei K; Laws SM; Macaulay SL; Bush AI; Ellis KA; Martins R; Ames D; Silbert B; Vanderstichele H; Masters CL; Darby DG; Li QX; Collins S;
    J Alzheimers Dis; 2018; 61(1):169-183. PubMed ID: 29171991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain metabolic correlates of CSF Tau protein in a large cohort of Alzheimer's disease patients: A CSF and FDG PET study.
    Chiaravalloti A; Barbagallo G; Ricci M; Martorana A; Ursini F; Sannino P; Karalis G; Schillaci O
    Brain Res; 2018 Jan; 1678():116-122. PubMed ID: 29066367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease.
    Heslegrave A; Heywood W; Paterson R; Magdalinou N; Svensson J; Johansson P; Öhrfelt A; Blennow K; Hardy J; Schott J; Mills K; Zetterberg H
    Mol Neurodegener; 2016 Jan; 11():3. PubMed ID: 26754172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amyloid PETs are commonly negative in suspected Alzheimer's disease with an increase in CSF phosphorylated-tau protein concentration but an Aβ42 concentration in the very high range: a prospective study.
    Manca C; Rivasseau Jonveaux T; Roch V; Marie PY; Karcher G; Lamiral Z; Malaplate C; Verger A
    J Neurol; 2019 Jul; 266(7):1685-1692. PubMed ID: 30963253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.
    Mattsson N; Insel PS; Donohue M; Landau S; Jagust WJ; Shaw LM; Trojanowski JQ; Zetterberg H; Blennow K; Weiner MW;
    Brain; 2015 Mar; 138(Pt 3):772-83. PubMed ID: 25541191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reference measurement procedure for CSF amyloid beta (Aβ)
    Pannee J; Portelius E; Minthon L; Gobom J; Andreasson U; Zetterberg H; Hansson O; Blennow K
    J Neurochem; 2016 Nov; 139(4):651-658. PubMed ID: 27579672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.